Clinical trialNCT02742090TerminatedPhase 2Interventional

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

SponsorTG Therapeutics, Inc.Enrollment51Chronic Lymphocytic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anthony Mato, MD
University of Pennsylvania Center for CLL
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Tg Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
Tg Therapeutics Investigational Trial Site
Washington D.C., District of Columbia, United States
Tg Therapeutics Investigational Trial Site
Fort Myers, Florida, United States
Tg Therapeutics Investigational Trial Site
St. Petersburg, Florida, United States
Tg Therapeutics Investigational Trial Site
Kansas City, Missouri, United States
Tg Therapeutics Investigational Trial Site
Lebanon, New Hampshire, United States
Tg Therapeutics Investigational Trial Site
Hackensack, New Jersey, United States
Tg Therapeutics Investigational Trial Site
New Hyde Park, New York, United States
Tg Therapeutics Investigational Trial Site
New York, New York, United States
Tg Therapeutics Investigational Trial Site
Rochester, New York, United States
Tg Therapeutics Investigational Trial Site
Durham, North Carolina, United States
Tg Therapeutics Investigational Trial Site
Hershey, Pennsylvania, United States
Tg Therapeutics Investigational Trial Site
Philadelphia, Pennsylvania, United States
Tg Therapeutics Investigational Trial Site
Nashville, Tennessee, United States
Tg Therapeutics Investigational Trial Site
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Umbralisib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Apr 2016
Primary completion: 10 Jun 2021
Completion: 10 Jun 2021
Last update posted: 3 Jul 2024
Registered enrollment: 51
Registry id: NCT02742090

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.